QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
TSE:PMN

ProMIS Neurosciences (PMN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free PMN Stock Alerts
Compare
Today's Range
N/A
50-Day Range
C$6.00
▼
C$6.00
52-Week Range
N/A
Volume
19,701 shs
Average Volume
3,327 shs
Market Capitalization
C$51.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisEarningsHeadlinesInsider Trades
PMN stock logo

About ProMIS Neurosciences Stock (TSE:PMN)

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

PMN Stock News Headlines

April 1, 2024 | msn.com
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
February 22, 2024 | finance.yahoo.com
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
February 1, 2024 | msn.com
Nerve stimulation plus physical rehabilitation may boost recovery of arm and hand function
January 8, 2024 | markets.businessinsider.com
ProMIS Neurosciences Issues Letter to Shareholders
December 20, 2023 | finanznachrichten.de
ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Publication on Novel Target for ALS
November 20, 2023 | markets.businessinsider.com
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 14, 2023 | finance.yahoo.com
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
September 8, 2023 | finance.yahoo.com
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
August 22, 2023 | marketwatch.com
ProMIS Neurosciences Shares Jump on $20.4 Million Private Placement
August 15, 2023 | finanznachrichten.de
ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023 | finance.yahoo.com
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 1, 2023 | seekingalpha.com
PMN ProMIS Neurosciences, Inc.
July 17, 2023 | marketwatch.com
Toronto Stocks Edge Lower; ProMIS Neurosciences Soars on Positive Alzheimer's Treatment Data
July 17, 2023 | msn.com
Alzheimer’s Drug Data Sends ProMIS Vaulting Up
July 17, 2023 | msn.com
Why ProMIS Neurosciences Stock Surged Today
July 17, 2023 | msn.com
ProMIS stock rockets 115% amid preclinical data for Alzheimer's drug
July 17, 2023 | finance.yahoo.com
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 14, 2023 | finance.yahoo.com
ProMIS Announces Completion of Continuance
July 10, 2023 | finanznachrichten.de
ProMIS Neurosciences Inc.: ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 10, 2023 | finance.yahoo.com
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
June 30, 2023 | finance.yahoo.com
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 29, 2023 | finance.yahoo.com
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
May 16, 2023 | finanznachrichten.de
ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 8, 2023 | finance.yahoo.com
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
April 27, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc up on Wednesday (PMN)
See More Headlines
Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:PMN
Previous Symbol
TSE:AMF
CUSIP
N/A
CIK
N/A
Web
www.promisneurosciences.com
Phone
+1-416-8476898
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C($3.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-20,930,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-837.71%
Return on Assets
-168.33%

Debt

Debt-to-Equity Ratio
108.33
Current Ratio
0.51
Quick Ratio
1.30

Sales & Book Value

Annual Sales
C$7,558.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
14.07
Book Value
C($0.72) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
8,580,000
Free Float
N/A
Market Cap
C$51.48 million
Optionable
Not Optionable
Beta
1.19
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Eugene Williams (Age 64)
    Co-Founder & Chairman
    Comp: $439.21k
  • Dr. Gail M. Farfel Ph.D. (Age 59)
    CEO & Director
    Comp: $177.23k
  • Dr. Neil R. Cashman M.D. (Age 71)
    Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
    Comp: $333.8k
  • Mr. Gavin T. Malenfant (Age 59)
    Chief Operating Officer
    Comp: $413.49k
  • Mr. Daniel E. Geffken M.B.A. (Age 66)
    MBA, Chief Financial Officer
  • Dr. Johanne Kaplan Ph.D. (Age 63)
    Chief Devel. Officer
  • Dr. Ernest D. Bush Ph.D.
    Head of Pharmacology/Toxicology & Sr. Consultant
  • Dr. David Wishart Ph.D.
    Chief Physics Officer
  • Mr. Dennis Chen Ph.D.
    Head of Manufacturing & Sr. Consultant
  • Dr. Larry Douglas Altstiel M.D. (Age 73)
    Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

PMN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ProMIS Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP).

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:PMN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Your Money is Not Safe
American Alternative
SHOCKING Crypto Leak…
Crypto 101 Media